Baseline elevated Lp-PLA2 is associated with increased risk for re-stenosis after stent placement. - Wikidata - awgldk - TriplyDB

Baseline elevated Lp-PLA2 is associated with increased risk for re-stenosis after stent placement.

Baseline elevated Lp-PLA2 is associated with increased risk for re-stenosis after stent placement.

http://www.wikidata.org/entity/Q37685077

about

Review on cardiovascular risk prediction.Pleiotropic effects of fenofibrate therapy on rats with hypertriglycemia.Effects and potential mechanism of atorvastatin treatment on Lp-PLA2 in rats with dyslipidemia.

P2860

Q38373055-D6EB224F-F2FC-4CEF-BA59-18A34EA42C8B Q39908570-AF51027E-1B66-45EE-A0EA-29BB5298A4C1 Q54109565-0A28D6E6-3141-4B6D-8C20-56F32036A8D8

P2860

Baseline elevated Lp-PLA2 is associated with increased risk for re-stenosis after stent placement.

http://www.wikidata.org/entity/Q37685077

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on March 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Baseline elevated Lp-PLA2 is a ...... tenosis after stent placement.

@en

Baseline elevated Lp-PLA2 is a ...... tenosis after stent placement.

@nl

type

label

Baseline elevated Lp-PLA2 is a ...... tenosis after stent placement.

@en

Baseline elevated Lp-PLA2 is a ...... tenosis after stent placement.

@nl

prefLabel

Baseline elevated Lp-PLA2 is a ...... tenosis after stent placement.

@en

Baseline elevated Lp-PLA2 is a ...... tenosis after stent placement.

@nl

P1433

Q37685077-F8E935F6-F1DA-4B55-B14E-AFC791236DC5

P1476

Q37685077-BC2C544A-B710-4621-B637-E161BCF1C60D

P2093

Q37685077-1F70527B-3D67-48B1-AE08-495D39A46311

Q37685077-3B902508-720D-4F89-9597-A02084811D3E

Q37685077-3DA1A31A-7E5A-431D-BC9C-B3870DCBFDCA

Q37685077-40C2D221-F568-4055-BBB8-4C3E9DC03A88

Q37685077-4F3798A8-01C3-4446-9051-4C9EB016F829

Q37685077-76F42D93-7C14-4D27-9EF6-B95539191FE4

Q37685077-A3C1054B-C1D5-4C05-A2CE-C42AC26D4370

Q37685077-B2904F28-AD51-4AAF-91BF-013EC83B0806

Q37685077-EAF9E2BA-3315-45F9-988E-C992F1052085

P2860

Q37685077-09780714-3C64-4DE8-84C6-E1DA4855AA32

Q37685077-0CCE0E61-0ED6-4C09-9471-079FA6828BE2

Q37685077-0E5C4C84-D73B-4B48-9C3B-B03B0619B1E5

Q37685077-13FAB03A-8486-4677-8817-AA3E313F4880

Q37685077-1C4C1EE5-C5C5-4146-A357-5F7973233845

Q37685077-2366C48B-18FE-405B-B9F4-20DF60324218

Q37685077-2E684F98-EF63-489E-87C6-97E5ACB6B6F0

Q37685077-33A4EDC1-12CE-4FA9-938D-0F6CC7D7E164

Q37685077-35FB72EA-5CB7-4327-8A1A-EE21E32911E5

Q37685077-36D1061F-66F9-4810-B36A-2540AD0C97E6

P2888

Q37685077-490985A1-806D-4365-BBC5-AF7B267D6BB2

P304

Q37685077-DB80B984-4F14-4591-AA3E-372B4C58F179

P31

Q37685077-0FE241CA-B768-405B-933B-6D8025508366

P356

Q37685077-16E5FCC5-314B-4E95-A55E-662D738DA597

P478

Q37685077-C662B7CD-EAA1-4BF7-A3F8-A5427DFA5D7F

P577

Q37685077-FC92CE10-CAFD-41D1-A21E-5A996336847F

P5875

Q37685077-5FA713DE-F242-400A-924D-26D7526DFD9B

P698

Q37685077-C8FF6E4C-8A50-40D8-8152-0437304403E6

P932

Q37685077-E7CB10B4-2760-4E06-A7C2-8C8BD619DF96

P356

1476-511X-13-41

P1433

Lipids in Health and Disease

P1476

Baseline elevated Lp-PLA2 is a ...... tenosis after stent placement.

@en

P2093

Anping Cai

http://www.w3.org/2001/XMLSchema#string

Chun Xiao

http://www.w3.org/2001/XMLSchema#string

Dongdan Zheng

http://www.w3.org/2001/XMLSchema#string

FanFang Zeng

http://www.w3.org/2001/XMLSchema#string

Huocheng Liao

http://www.w3.org/2001/XMLSchema#string

Ling Liu

http://www.w3.org/2001/XMLSchema#string

Rulin Xu

http://www.w3.org/2001/XMLSchema#string

Ruofeng Qiu

http://www.w3.org/2001/XMLSchema#string

Weiyi Mai

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development

Atherosclerosis — An Inflammatory Disease

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association

Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review.

Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) and risk of cardiovascular disease in older adults: results from the Cardiovascular Health Study.

Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies.

High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.

Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.

P2888

1476-511x-13-41

P304

41

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1476-511X-13-41

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2014-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260442659

http://www.w3.org/2001/XMLSchema#string

P698

24580749

http://www.w3.org/2001/XMLSchema#string

P932

3975936

http://www.w3.org/2001/XMLSchema#string